Overview

The marketing authorisation for this product has been withdrawn at the request of the marketing authorisation holder.

български (BG) (394.36 KB - PDF)

View

español (ES) (273.62 KB - PDF)

View

čeština (CS) (732.68 KB - PDF)

View

dansk (DA) (455.05 KB - PDF)

View

Deutsch (DE) (279.59 KB - PDF)

View

eesti keel (ET) (286.49 KB - PDF)

View

ελληνικά (EL) (364.56 KB - PDF)

View

français (FR) (302.11 KB - PDF)

View

italiano (IT) (274.63 KB - PDF)

View

latviešu valoda (LV) (327.75 KB - PDF)

View

lietuvių kalba (LT) (319.37 KB - PDF)

View

magyar (HU) (319.09 KB - PDF)

View

Malti (MT) (349.32 KB - PDF)

View

Nederlands (NL) (277.61 KB - PDF)

View

polski (PL) (557.29 KB - PDF)

View

português (PT) (297.96 KB - PDF)

View

română (RO) (502.78 KB - PDF)

View

slovenčina (SK) (321.18 KB - PDF)

View

slovenščina (SL) (327.97 KB - PDF)

View

Suomi (FI) (296.79 KB - PDF)

View

svenska (SV) (274.99 KB - PDF)

View

Product information

български (BG) (854.08 KB - PDF)

View

español (ES) (446.08 KB - PDF)

View

čeština (CS) (960.58 KB - PDF)

View

dansk (DA) (942.41 KB - PDF)

View

Deutsch (DE) (454 KB - PDF)

View

eesti keel (ET) (445.99 KB - PDF)

View

ελληνικά (EL) (796.2 KB - PDF)

View

français (FR) (469.55 KB - PDF)

View

hrvatski (HR) (474.59 KB - PDF)

View

íslenska (IS) (521.51 KB - PDF)

View

italiano (IT) (449.11 KB - PDF)

View

latviešu valoda (LV) (645.13 KB - PDF)

View

lietuvių kalba (LT) (450.71 KB - PDF)

View

magyar (HU) (640.36 KB - PDF)

View

Malti (MT) (642.9 KB - PDF)

View

Nederlands (NL) (448.33 KB - PDF)

View

norsk (NO) (777.6 KB - PDF)

View

polski (PL) (1.01 MB - PDF)

View

português (PT) (465.13 KB - PDF)

View

română (RO) (759.05 KB - PDF)

View

slovenčina (SK) (601.1 KB - PDF)

View

slovenščina (SL) (619.58 KB - PDF)

View

Suomi (FI) (448.79 KB - PDF)

View

svenska (SV) (437.53 KB - PDF)

View

Latest procedure affecting product information: IG/0747

23/03/2017

български (BG) (624.22 KB - PDF)

View

español (ES) (222.31 KB - PDF)

View

čeština (CS) (433.35 KB - PDF)

View

dansk (DA) (226.08 KB - PDF)

View

Deutsch (DE) (183.4 KB - PDF)

View

eesti keel (ET) (220.22 KB - PDF)

View

ελληνικά (EL) (432.41 KB - PDF)

View

français (FR) (221.57 KB - PDF)

View

italiano (IT) (219.75 KB - PDF)

View

latviešu valoda (LV) (273.68 KB - PDF)

View

lietuvių kalba (LT) (420.63 KB - PDF)

View

magyar (HU) (379.71 KB - PDF)

View

Malti (MT) (277.41 KB - PDF)

View

Nederlands (NL) (226.13 KB - PDF)

View

polski (PL) (271.54 KB - PDF)

View

português (PT) (380.5 KB - PDF)

View

română (RO) (255.01 KB - PDF)

View

slovenčina (SK) (270.57 KB - PDF)

View

slovenščina (SL) (267.88 KB - PDF)

View

Suomi (FI) (219.04 KB - PDF)

View

svenska (SV) (387.87 KB - PDF)

View

Product details

Name of medicine
Zulvac 8 Bovis
Active substance
inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02
International non-proprietary name (INN) or common name
inactivated bluetongue virus, serotype 8
Species
Cattle
Anatomical therapeutic chemical veterinary (ATCvet) code
QI02AA08

Pharmacotherapeutic group

Immunologicals

Therapeutic indication

Active immunisation of cattle from three months of age for the prevention of viraemia caused by bluetongue virus, serotype 8.

Authorisation details

EMA product number
EMEA/V/C/000145
Marketing authorisation holder
Zoetis Belgium

Zoetis Belgium
Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Marketing authorisation issued
15/01/2010
Revision
7

Assessment history

News on Zulvac 8 Bovis

Topics

This page was last updated on

Share this page